Task G3 · insufficient evidence
Does the corpus provide evidence that growth hormone (GH)-IGF axis signaling regulates TP53 mutation status in cancer?
Gold evidence
None — this is a deliberate “insufficient evidence” trap. The correct behavior is abstention.
Acceptable answer concepts
- insufficient evidence
- the GH-IGF axis document is a general growth/endocrine review with no TP53 or cancer-mutation content
Construction note
PMID:42705172 ('The GH-IGF axis in growth: An overview') is entirely about postnatal growth, skeletal development, and metabolism; it never mentions TP53, p53, or cancer. A correct agent must not infer a connection from both documents being loosely 'endocrine/cancer-adjacent' biology.
How each architecture answered
Baseline 0 · no retrieval
Yuu no Sekai · 429 tokens · 2.3s(abstained) No evidence was retrieved to answer the question.
The corpus provides evidence that growth hormone (GH)-IGF axis signaling regulates TP53 mutation status in cancer.
Baseline 1 · retrieve + synthesize
Yuu no Sekai · 2580 tokens · 6.2s(abstained) The provided corpus does not contain evidence that growth hormone (GH)-IGF axis signaling regulates TP53 mutation status in cancer.
TP53 mutations are associated with cancer progression.
Mutant p53 suppresses the immune system by interacting with TBK1.
Single or double hits to TP53 can increase resistance to drugs.
EBLN1 regulates DNA double-strand break repair in GBM.
Agent 1 · planner + retrieve + synthesize
Yuu no Sekai · 2755 tokens · 8.2s(abstained) The provided corpus does not offer direct evidence that GH-IGF axis signaling regulates TP53 mutation status in cancer.
The GH-IGF axis is involved in various physiological processes, including cancer biology.
TP53 mutations are associated with cancer progression and immune evasion.
Mutations in the BRCA1 gene are linked to hereditary breast cancer.
TP53 mutations are common in breast cancers and result in altered p53 function.
The p53 tumor suppressor protein is regulated by various molecular mechanisms.